Previous 10 |
vTv Therapeutics Inc. ( VTVT) is a pharmaceutical company with 7 drug candidates currently in different clinical stages. The programs are mainly focused on Alzheimer’s disease, diabetes, and inflammation. However, its most promising candidate, azeliragon, just failed Phase 3 trial for ...
vTv Therapeutics (NASDAQ: VTVT ): Q4 GAAP EPS of -$0.10. More news on: vTv Therapeutics, Earnings news and commentary, Healthcare stocks news, , Read more ...
vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the fourth quarter and year that ended December 31, 2018, and provided an update on recent achievements and upcoming events. “We are excited about the therapeutic potential of azeliragon in patients with ...
Fortress Biotech (NASDAQ: FBIO ) +56% on Caelum deal with Alexion. More news on: Fortress Biotech, Inc., Prana Biotechnology Ltd, VistaGen Therapeutics, Inc., Stocks on the move, , Read more ...
CORAL GABLES, FL / ACCESSWIRE / January 25, 2019 / The healthcare stock market has become increasingly more exciting over the last few months, with headlines detailing inventive treatments and strategic acquisitions popping up left and right. Companies in the healthcare industry have rec...
This article serves as a portfolio-based market barometer that shows which types of portfolio algorithms are outperforming from week to week. Leveraging different forensic, value, fundamental, momentum, and anomaly portfolios, we may be able to anticipate changes not only in market direction b...
Gainers: Triumph Group (NYSE: TGI ) +27% . ToughBuilt Industries (NASDAQ: TBLT ) +25% . Kazia Therapeutics (NASDAQ: KZIA ) +26% . vTv Therapeutics (NASDAQ: VTVT ) +18% . Xilinx (NASDAQ: XLNX ) +18% . Resonant (NASDAQ: RESN ) +13% . ASLAN Pharmaceuticals (NASDAQ: ASLN ) +16% . ...
News, Short Squeeze, Breakout and More Instantly...
vTv Therapeutics Inc. Company Name:
VTVT Stock Symbol:
NASDAQ Market:
vTv Therapeutics Inc. Website:
HIGH POINT, N.C., July 26, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead program in diabetes, today announced that the United States Food and Drug Administration (FDA) has pla...
2024-06-26 16:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Cadisegliatin is a potential first-in-class oral liver selective glucokinase activator for T1D, which has been granted Breakthrough Therapy designation by the FDA for T1D Cadisegliatin has been dosed in over ...